Literature DB >> 11469990

Nonulcer Dyspepsia.

Guy E. E. Boeckxstaens1.   

Abstract

There is currently no effective treatment for patients with nonulcer dyspepsia. Helicobacter pylori eradication has no beneficial effect on dyspeptic symptoms. Proton pump inhibitors are superior to placebo in the subset of patients with epigastric pain as the predominant symptom. H(2 )Receptor antagonists have no effect. Patients with dysmotility-like dyspepsia should be treated first with prokinetics. Unfortunately, cisapride no longer can be used to treat patients with functional dyspepsia because of reports of serious cardiovascular side effects and subsequent withdraw from the US market. Therefore, metoclopramide (or domperidone, if available) should be given. Treatment with motilides has no use in the relief of symptoms, even in patients with delayed gastric emptying. If the initial therapy has no effect after 4 weeks, switch treatment (eg, from proton pump inhibitor to metoclopramide or vice versa). If both of these pharmacologic therapies fail, consider treatment with an antidepressant (or with buspirone, an anxiolytic agent) or psychotherapy.

Entities:  

Year:  2001        PMID: 11469990     DOI: 10.1007/s11938-001-0057-8

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  26 in total

1.  Development of a test to measure gastric accommodation in humans.

Authors:  S D Kuiken; M Samsom; M Camilleri; B P Mullan; D D Burton; L J Kost; T J Hardyman; B H Brinkmann; M K O'Connor
Journal:  Am J Physiol       Date:  1999-12

Review 2.  Functional gastroduodenal disorders.

Authors:  N J Talley; V Stanghellini; R C Heading; K L Koch; J R Malagelada; G N Tytgat
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

3.  Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia.

Authors:  J S Finney; N Kinnersley; M Hughes; C G O'Bryan-Tear; J Lothian
Journal:  J Clin Gastroenterol       Date:  1998-06       Impact factor: 3.062

4.  Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia.

Authors:  G Holtmann; J Gschossmann; M Karaus; T Fischer; B Becker; P Mayr; G Gerken
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

5.  Predominant symptoms identify different subgroups in functional dyspepsia.

Authors:  V Stanghellini; C Tosetti; A Paternicò; R De Giorgio; G Barbara; B Salvioli; R Corinaldesi
Journal:  Am J Gastroenterol       Date:  1999-08       Impact factor: 10.864

6.  Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis.

Authors:  C Mansi; P Borro; M Giacomini; R Biagini; M R Mele; N Pandolfo; V Savarino
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

7.  Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.

Authors:  A L Blum; R Arnold; M Stolte; M Fischer; H R Koelz
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

8.  Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia.

Authors:  N W Read; J L Abitbol; K D Bardhan; P J Whorwell; B Fraitag
Journal:  Gut       Date:  1997-11       Impact factor: 23.059

9.  Drug-induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions.

Authors:  P Bytzer; J Hallas
Journal:  Aliment Pharmacol Ther       Date:  2000-11       Impact factor: 8.171

10.  Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia.

Authors:  C Feinle; O Meier; B Otto; M D'Amato; M Fried
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.